Infection and infestation-related adverse events of ocrelizumab: A disproportionality analysis using FDA adverse event reporting system.
Duman, Nesrin Caglayan. 2025. “Infection and Infestation-Related Adverse Events of Ocrelizumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.”. Northern Clinics of Istanbul 12 (5): 569-75.